The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future

Andermann, Tessa M.; Peled, Jonathan U.; Ho, Christine M.; Reddy, Pavan; Riches, Marcie L.; Storb, Rainer; Teshima, Takanori; Brink, Marcel R.M. van den; Alousi, Amin M.; Balderman, Sophia R.; Chiusolo, Patrizia; Clark, William; Holler, Ernst; Howard, Alan; Kean, Leslie S.; Koh, Andrew Y.; McCarthy, Philip L.; McCarty, John M.; Mohty, Mohamad; Nakamura, Ryotaro; Rezvani, Katy; Segal, Brahm H.; Shaw, Bronwen E.; Shpall, Elizabeth J.; Sung, Anthony D.; Weber, Daniela; Whangbo, Jennifer; Wingard, John R.; Wood, William A.; Perales, Miguel-Ángel; Jenq, Robert R.; Bhatt, Ami S.

doi:10.1016/j.bbmt.2018.02.009

Cited by 95 publications

(67 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surprisingly, in the 1970s some of the earliest animal studies of bone marrow transplantation hinted at a role for the microbiota in GvHD, and this evidence continues to accumulate. For a detailed bibliography on the microbiota and HCT outcomes, please see several informative recent reviews (22)(23)(24). This Review will focus on the microbiota as it relates to GvHD, and specifically the bacterial biota, though fungi and viruses may also play a role.…”

Section: The Microbiota and Gvhdmentioning

confidence: 99%

The gut microbiota and graft-versus-host disease

Fredricks¹

2019

Journal of Clinical Investigation

View full text Add to dashboard Cite

Section: The Microbiota and Gvhdmentioning

confidence: 99%

The gut microbiota and graft-versus-host disease

Fredricks¹

2019

Journal of Clinical Investigation

View full text Add to dashboard Cite

“…Microbiota modulation through FMT is increasingly being reported in case reports and pilot clinical trials of HSCT recipients as treatment of steroid-refractory or steroid-resistant gastrointestinal (GI) acute graft-versus-host disease (aGVHD). The development of GI aGVHD has long been correlated with both community-and species-level changes in the intestinal microbiota although primarily in small single-center studies (for a review of this topic, see Andermann et al 19 ). Researchers have demonstrated that decreased microbial diversity at the time of engraftment is associated with higher mortality.…”

Section: Fmt As Treatment and Prevention Of Complications In Hsct Recmentioning

confidence: 99%

Microbiota modification in hematology: still at the bench or ready for the bedside?

2019

Self Cite

View full text Add to dashboard Cite

Growing evidence suggests that human microbiota likely influence diverse processes including hematopoiesis, chemotherapy metabolism, and efficacy, as well as overall survival in patients with hematologic malignancies and other cancers. Both host genetic susceptibility and host-microbiota interactions may impact cancer risk and response to treatment; however, microbiota have the potential to be uniquely modifiable and accessible targets for treatment. Here, we focus on strategies to modify microbiota composition and function in patients with cancer. First, we evaluate the use of fecal microbiota transplant to restore microbial equilibrium following perturbation by antibiotics and chemotherapy, and as a treatment of complications of hematopoietic stem cell transplantation (HSCT), such as graft-versus-host disease and colonization with multidrug-resistant organisms. We then address the potential use of both probiotics and dietary prebiotic compounds in targeted modulation of the microbiota intended to improve outcomes in hematologic diseases. With each type of therapy, we highlight the role that abnormal, or dysbiotic, microbiota play in disease, treatment efficacy, and toxicity and evaluate their potential promise as emerging strategies for microbiota manipulation in patients with hematologic malignancies and in those undergoing HSCT.

show abstract

“…The role of the microbiome in intestinal damage and dysfunction in children with cancer is an emerging area of research. Alterations in the microbiome have been documented in patients undergoing HSCT and associated with adverse transplant outcomes . Multiple influencing factors have been proposed including use of prophylactic antibiotics, neutropenic diet, and PN.…”

Section: Principles Of Management In Children With Cancer and Intestimentioning

confidence: 99%

“…Alterations in the microbiome have been documented in patients undergoing HSCT and associated with adverse transplant outcomes. 50 Multiple influencing factors have been proposed including use of prophylactic antibiotics, neutropenic diet, and PN. Future research in children undergoing HSCT will help to elucidate the role of microbiome assessment and management.…”

Section: Nutritional Supportmentioning

confidence: 99%

Parenteral nutrition use in children with cancer

McGrath

2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Multiple disease and treatment‐related factors contribute to intestinal insult and influence the nutritional status of children with cancer. Many children with cancer will experience intestinal dysfunction during their cancer journey and children with cancer are a common referral group for inpatient parenteral nutrition. Appropriate use of parenteral nutrition in children with cancer and intestinal failure may alleviate malnutrition and associated risks. However, proper selection of patients, correct parenteral nutrition prescription, and close monitoring is important to avoid unnecessary intestinal failure or parenteral nutrition–related complications, minimize long‐term nutritional sequelae or additional costs to health services, and optimize intestinal rehabilitation.

show abstract

The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future

Cited by 95 publications

References 155 publications

The gut microbiota and graft-versus-host disease

The gut microbiota and graft-versus-host disease

Microbiota modification in hematology: still at the bench or ready for the bedside?

Parenteral nutrition use in children with cancer

Contact Info

Product

Resources

About